Skip to main content

Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617

Molecular Imaging and Biology volume 18, pages 437–445 (2016)Cite this article

Abstract

Purpose

Calculating the absorbed dose is important for the determination of risk and therapeutic benefit of internal radiation therapy. The aim of this study was to perform image-based absorbed dose calculation for critical organs during the first cycle of [177Lu]DKFZ-PSMA-617 therapy in a small cohort of patients with metastatic prostate cancer.

Procedures

Nine patients with a history of prostate cancer documented by histopathology and radiologic evidence of metastatic diseases underwent radioligand therapy with [177Lu]DKFZ-PSMA-617. Conjugated planar whole-body scintigraphies acquired at 0.5, 24, 48, 72, and 168 h post-injection were analyzed by regions of interest, and time-activity curves were generated for various organs. Cumulated activities and residence times were calculated by bi-exponential fit of the time-activity curves. Mean absorbed doses were finally estimated using OLINDA/EXM1.1™. Additionally, the uncertainty when omitting the last measurement (168 h p.i.) was studied.

Results

The following mean absorbed doses were calculated: 2.82 mGy/MBq for the lacrimal glands, 0.72 mGy/MBq for the salivary glands, 0.53 mGy/MBq for the kidneys, and 0.42 mGy/MBq for the nasal mucous membrane. Omitting the last measurement resulted in a mean deviation of 10 to 25 % for absorbed dose values as compared to the ones received by analyzing all measurements.

Conclusion

Absorbed organ doses of [177Lu]DKFZ-PSMA-617 therapy are not likely to be critical for kidneys, salivary glands, and the nasal mucous membrane. The lacrimal glands may represent the dose-limiting organs. Whole-body scintigraphy appears sufficient for dose estimation, but late measurements are mandatory, if accurate dose calculation is required.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386

    CAS  Article  PubMed  Google Scholar 

  2. Zechmann CM, Afashar-Oromieh A, Armor T et al (2014) Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 41:1280–1292

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Bacich DJ, Pinto JT, Tong WP, Heston WD (2001) Cloning expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 12:117–123

    CAS  Article  PubMed  Google Scholar 

  4. Perner S, Hofer MD, Kim R et al (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer. Hum Pathol 38:696–701

    CAS  Article  PubMed  Google Scholar 

  5. Bradford TJ, Tomlins SA, Wang X, Chinnaiyan AM (2006) Molecular markers of prostate cancer. Urol Oncol 24:538–551

    CAS  Article  PubMed  Google Scholar 

  6. Bander NH, Milowsky MI, Nanus DM et al (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23:4591–4601

    CAS  Article  PubMed  Google Scholar 

  7. Foss CA, Mease RC, Fan H et al (2005) Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 11:4022–4028

    CAS  Article  PubMed  Google Scholar 

  8. Humblet V, Lapidus R, Williams LR et al (2005) High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging 4:448–462

    PubMed  Google Scholar 

  9. Pomper MG, Musachio JL, Zhang J et al (2002) 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging 1:96–101

    CAS  Article  PubMed  Google Scholar 

  10. Eder M, Schafer M, Bauder-Wust U et al (2012) 68Ga-complex lipophilicity and targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688–697

    CAS  Article  PubMed  Google Scholar 

  11. Afshar-Oromieh A, Haberkorn U, Hadaschik B et al (2013) PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging 40:1629–1630

    Article  PubMed  Google Scholar 

  12. Eiber M, Nekolla SG, Maurer T et al (2014) Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging 40:1769–1771

    Article  Google Scholar 

  13. Tasch J, Gong M, Sadelain M, Heston WD (2001) A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol 21:249–261

    CAS  Article  PubMed  Google Scholar 

  14. Kratochwil C, Giesel FL, Eder M et al (2015) [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 42:987–988

    Article  PubMed  Google Scholar 

  15. Bé MM, Chisté V, Dulie C, et al (2004) Table of radionuclides (Vol. 2-A = 151 to 242). Bureau international des poids et mesures, Pavillon de Breteuil, Sèvres

  16. Hindorf C, Glatting G, Chiesa C, Lindén O et al (2010) EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry. Eur J Med Mol Imgaging 37:1238–1250

    Article  Google Scholar 

  17. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023–1027

    PubMed  Google Scholar 

  18. Snyder WS, Fischer HL Jr, Ford MR, Warner GG (1969) Estimate of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. MIRD pamphlet no. 5. J Nucl Med 10:7–52

    Google Scholar 

  19. Loevinger R, Budinger TF, Watson EE (1988) MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, New York

    Google Scholar 

  20. Snyder WS, Cook MJ, Nasset ES, et al (1979) Report of the task group on reference man. ICRP Publication 23

  21. Bukhari AA, Basheer NA, Joharjy HI (2014) Age, gender and interracial variability of normal lacrimal gland volume using MRI. Ophthal Plast Reconstr Surg 30:388–391

    Article  PubMed  Google Scholar 

  22. Bingham CM, Castro A, Realini T et al (2013) Calculated CT volumes of lacrimal glands in normal Caucasian orbits. Ophthal Plast Reconstr Surg 29:157–159

    Article  PubMed  Google Scholar 

  23. Garkavij M, Nickel M, Sjögreen-Gleisner K et al (2010) 177Lu-[DOTA0, Tyr3] Octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer 116:1084–1092

    CAS  Article  PubMed  Google Scholar 

  24. Sandström M, Garske U, Granberg D et al (2010) Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate. Eur J Nucl Med Mol Imaging 37:212–225

    Article  PubMed  Google Scholar 

  25. Delker A, Fendler WP, Kratochwil C et al (2016) Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 43:42–51

    CAS  Article  PubMed  Google Scholar 

  26. Weineisen M, Schottelius M, Simecek J et al (2015) 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56:1169–1176

    CAS  Article  PubMed  Google Scholar 

  27. Pandit-Taskar N, O’Donoghue JA, Durack JC et al (2015) A phase I/II study for analytic validation of 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer. Clin Cancer Res 21:5277–5285

    CAS  Article  PubMed  Google Scholar 

  28. Banerjee SR, Foss CA, Castanares M et al (2008) Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 51:4504–4517

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. Maurer T, Weirich G, Schottelius M et al (2015) Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol 68:530–534

    Article  PubMed  Google Scholar 

  30. Benesova M, Schafer M, Bauder-Wust U et al (2015) Preclinical evaluation of a tailormade DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 56:914–920

    CAS  Article  PubMed  Google Scholar 

  31. Ahmadzadehfar H, Rahbar K, Kurpig S et al (2015) Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. doi:10.1186/s13550-015-0114-2

    Google Scholar 

  32. Pfestroff A, Luster M, Jilg CA et al (2015) Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks. Eur J Nucl Med Mol Imaging 42:1971–1975

    CAS  Article  PubMed  Google Scholar 

  33. Parsons JT, Bova FJ, Mendenhall WM et al (1996) Response of the normal eye to high dose radiotherapy. Oncology 10:837–847

    CAS  PubMed  Google Scholar 

  34. Buchali A, Schröder C, Sidow D, Blank E (1991) Influence of the radiation dose to salivary glands on xerostomia in patients with head and neck carcinomas. J Cancer Ther 4:188–194

    Article  Google Scholar 

  35. Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122

    CAS  Article  PubMed  Google Scholar 

  36. Yin G, Xiong G, Zhao C, Chen Y (2010) Damage of nasal mucociliary movement after intensity-modulated radiation therapy of nasopharyngeal carcinoma. Chin J Cancer 29:824–829

    Article  PubMed  Google Scholar 

  37. Larson M, Bernhardt P, Svensson JB et al (2012) Estimation of absorbed dose to the kidneys in patients with 177Lu-octreotate: comparison between methods based on planar scintigraphy. EJNMMI Res. doi:10.1186/2191-219X-2-49

    Google Scholar 

  38. Siegel JA, Thomas SR, Stubbs JB et al (1999) MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40:37S–61S

    CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50937, Germany

    Melanie Hohberg, Wolfgang Eschner, Matthias Schmidt, Markus Dietlein, Carsten Kobe, Thomas Fischer, Alexander Drzezga & Markus Wild

Authors
  1. Melanie Hohberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Eschner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthias Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Markus Dietlein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carsten Kobe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thomas Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alexander Drzezga
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Markus Wild
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melanie Hohberg.

Ethics declarations

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hohberg, M., Eschner, W., Schmidt, M. et al. Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617. Mol Imaging Biol 18, 437–445 (2016). https://doi.org/10.1007/s11307-016-0942-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-016-0942-0

Key words

  • Prostate cancer
  • PSMA
  • Dosimetry
  • Lacrimal glands
  • Radioligand radiation therapy